Live Biotherapeutics Drug Discovery Service for Crohn's Disease (CD)
Creative Biolabs is a premium contract research services firm offering quality services and products. Our team has demonstrated independent research capabilities and delivered innovative solutions during the live biotherapeutics program. Our scientists have accumulated rich experience in the research of microbiology, probiotics, next-generation probiotics, and live biotherapeutics. Over the years, we have established an unparalleled record of delivering projects on time and efficiently.
Overview
The human gut has a complex microbial ecosystem, and the deviation of intestinal microbial balance may affect the host metabolism, leading to Crohn's disease (CD). CD can affect all parts of the digestive tract, from the mouth to the anus. It has a discontinuous character (alternating between inflamed tissue and noninflamed sites). CD can involve any segment of the gastrointestinal tract, mainly involving the rectum, colon, and ileum regions in an asymmetric, segmental, and transmural manner. The CD is manifested as a remission and activation phase and mainly involves 20-30 years. Probiotics are among the treatments that have been tested for the prevention and treatment of inflammatory diseases of the GI tract and are effective in treating lifestyle disorders and improving gut health. The alteration of intestinal flora is a key factor in the pathogenesis of CD. A large number of studies have confirmed that there is an important relationship between intestinal flora imbalance and postoperative recurrence of CD.
Targeted Therapy in CD
In the past two decades, the treatment of CD has expanded from glucocorticoids as the cornerstone of induction therapy to immunomodulators, nutritional therapy, biologics, and new small-molecule therapies.
Probiotics are composed of groups of living microorganisms that are thought to have health benefits. Microorganisms used as probiotics include Lactobacillus spp, Bifidobacterium spp, Streptococcus salivarius spp, yeasts, and E. coli Nissle 1917. Probiotic treatment can down-regulate the secretion of proinflammatory cytokines TNF-alpha, and IFN-gamma, and directly interfere with the activation of NF-kB. Probiotics can also secrete many active metabolites, exerting various anti-inflammatory and protective effects on cells. It is believed that the use of these metabolites overcomes the risk of infection associated with the ingestion of bacteria.
Fig.1 Summary of probiotic anti-inflammatory effects in intestinal chronic diseases in different scientific approaches.1
-
Faecal Microbial Transplant (FMT)
FMT involves injecting the fecal microbiota of a healthy donor into the gastrointestinal tract of a recipient.
Available Probiotic Strains for CD Research at Creative Biolabs
Creative Biolabs can offer a range of next-generation probiotics for live biotherapeutics research, including but not limited to the following, click on Probiotic Strains to check out more strains you might be interested in.
Our Services for the Following Type/Similar CD Research
|
Research Article
|
Available Services
|
|
Lactobacillus casei DN-114 001 inhibits the ability of adherent-invasive Escherichia coli to adhere to and invade intestinal epithelial cells.2
|
-
Adhesion and invasion inhibition assays
-
Epithelial cell viability
|
|
The extracellular proteins of Lactobacillus acidophilus display anti-inflammatory effects in Crohn's Disease patients.3
|
-
Cytokine quantification
-
Hematological analysis and immunological phenotyping
|
|
Anti-inflammatory and immunomodulatory efficacy of indigenous probiotic Lactobacillus plantarum Lp91 in colitis mouse model.4
|
|
Creative Biolabs has successfully worked with pharmaceutical companies, biotech startups, and academic research communities on significant projects. Our experts and technical team have a deep professional background. For more information on how we can accelerate your success, contact us now.
References
-
Plaza-Díaz, Julio, et al. "Evidence of the anti-inflammatory effects of probiotics and synbiotics in intestinal chronic diseases." Nutrients 9.6 (2017): 555.
-
Ingrassia, Isabelle, Antony Leplingard, and Arlette Darfeuille-Michaud. "Lactobacillus casei DN-114 001 inhibits the ability of adherent-invasive Escherichia coli isolated from Crohn's disease patients to adhere to and to invade intestinal epithelial cells." Applied and Environmental Microbiology 71.6 (2005): 2880-2887.
-
Hidalgo-Cantabrana, Claudio, et al. "The extracellular proteins of Lactobacillus acidophilus DSM 20079T display anti-inflammatory effect in both in piglets, healthy human donors and Crohn's Disease patients." Journal of Functional Foods 64 (2020): 103660.
-
Duary, Raj Kumar, et al. "Anti-inflammatory and immunomodulatory efficacy of indigenous probiotic Lactobacillus plantarum Lp91 in colitis mouse model." Molecular biology reports 39 (2012): 4765-4775.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
Related Services
